Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders off J Movement Disorder Society 16(3):448–458. https://doi.org/10.1002/mds.1090

Article  CAS  Google Scholar 

Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 9(6):859–867. https://doi.org/10.1586/ern.09.48

Article  CAS  PubMed  Google Scholar 

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, GLORIA study co-investigators, (2017) Levodopa–carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018

Article  PubMed  Google Scholar 

Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA (2018a) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34(12):2063–2073. https://doi.org/10.1080/03007995.2018.1502165

Article  PubMed  Google Scholar 

Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W (2018b) Age/disease duration influence on activities of daily living and quality of life after levodopa–carbidopa intestinal gel in Parkinson’s disease. Neurodegenerative Disease Management 8(3):161–170. https://doi.org/10.2217/nmt-2017-0046

Article  PubMed  Google Scholar 

Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, Jimenez-Shahed J, Alobaidi A, Jalundhwala YJ, Bao Y, Zamudio J, Parra JC, Kukreja P, Onuk K, Skalicky AM, Kleinman L, Jones E, Metz S, Fernandez HH (2021) Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson’s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord 92:59–66. https://doi.org/10.1016/j.parkreldis.2021.10.009

Article  CAS  PubMed  Google Scholar 

Auffret M, Drapier S, Vérin M (2018) Pharmacological insights into the use of Apomorphine in Parkinson’s disease: clinical relevance. Clin Drug Investig 38(4):287–312. https://doi.org/10.1007/s40261-018-0619-3

Article  CAS  PubMed  Google Scholar 

Cha Y, Park TY, Leblanc P, Kim KS (2023) Current status and future perspectives on stem cell-based therapies for parkinson’s disease. J Movement Disorders 16(1):22–41. https://doi.org/10.14802/jmd.22141

Article  Google Scholar 

Chaudhuri KR, Leta V (2022) Apomorphine infusion for improving sleep in Parkinson’s disease. The Lancet Neurology 21(5):395–398. https://doi.org/10.1016/S1474-4422(22)00128-4

Article  CAS  PubMed  Google Scholar 

Chaudhuri KR, Kovács N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, Cubo E, Anca-Herschkovitsch M, Iansek R, Siddiqui MS, Simu M, Bergmann L, Ballina M, Kukreja P, Ladhani O, Jia J, Standaert DG (2023) Levodopa Carbidopa intestinal gel in advanced Parkinson’s disease: DUOGLOBE Final 3-year results. J Parkinsons Dis 13(5):769–783. https://doi.org/10.3233/JPD-225105

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciurleo R, Corallo F, Bonanno L, Lo Buono V, Di Lorenzo G, Versaci R, Allone C, Palmeri R, Bramanti P, Marino S (2018) Assessment of duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers. J Neurol 265(9):2005–2014. https://doi.org/10.1007/s00415-018-8951-3

Article  PubMed  Google Scholar 

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European academy of neurology/movement disorder society-European section guideline on the treatment of Parkinson’s disease: I invasive therapies. Move Disorder : off J Movement Disorder Society 37(7):1360–1374. https://doi.org/10.1002/mds.29066

Article  Google Scholar 

di Biase L, Pecoraro PM, Carbone SP, Caminiti ML, Di Lazzaro V (2023) Levodopa-induced Dyskinesias in Parkinson’s disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions. J Clin Med 12(13):4427. https://doi.org/10.3390/jcm12134427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C. W., Tanner, C., Marek, K., Parkinson Study Group (2004). Levodopa and the progression of Parkinson’s disease. The New England journal of medicine, 351 (24), 2498–2508. Doi https://doi.org/10.1056/NEJMoa033447

Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y (2021) ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson’s disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord 91:139–145. https://doi.org/10.1016/j.parkreldis.2021.09.024

Article  CAS  PubMed  Google Scholar 

Hauser RA, Zeitlin L, Fisher S, D’Souza R (2021) Duration of benefit per dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). Parkinsonism Relat Disord 82:133–137. https://doi.org/10.1016/j.parkreldis.2020.12.002

Article  CAS  PubMed  Google Scholar 

Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Movement Disorders : off J Move Disorder Society 20(2):190–199. https://doi.org/10.1002/mds.20324

Article  Google Scholar 

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicentre study of effects on nonmotor symptoms and quality of life. Movem Disorders : off J Move Disorder Society 24(10):1468–1474. https://doi.org/10.1002/mds.22596

Article  Google Scholar 

Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., Rascol, O., Sampaio, C., European Federation of Neurological Societies, and Movement Disorder Society-European Section (2006). Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. European journal of neurology, 13 (11), 1186–1202. Doi https://doi.org/10.1111/j.1468-1331.2006.01548.x

Jenner P (2013) Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson’s disease. Neurol Clin 31(3 Suppl):S17–S35. https://doi.org/10.1016/j.ncl.2013.04.010

Article  PubMed  Google Scholar 

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet Neurology 17(9):749–759. https://doi.org/10.1016/S1474-4422(18)30239-4

Article  CAS  PubMed  Google Scholar 

Krüger R, Klucken J, Weiss D, Tönges L, Kolber P, Unterecker S, Lorrain M, Baas H, Müller T, Riederer P (2017) Classification of advanced stages of Parkinson’s disease: translation into stratified treatments. J Neural Transmission (vienna, Austria 1996) 124(8):1015–1027. https://doi.org/10.1007/s00702-017-1707-x

Article  Google Scholar 

Lau, Y. H., Leta, V., Rukavina, K., Parry, M., Ann Natividad, J., Metta, V., Chung-Faye, G., & Chaudhuri, K. R. (2022). Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease. Journal of neural transmission (Vienna, Austria : 1996), 129 (7), 889–894. Doi https://doi.org/10.1007/s00702-022-02506-4

Leta V, van Wamelen DJ, Sauerbier A, Jones S, Parry M, Rizos A, Chaudhuri KR (2020) Opicapone and Levodopa–carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis 10(4):1535–1539. https://doi.org/10.3233/JPD-202022

Article  PubMed  Google Scholar 

Leta V, Dafsari HS, Sauerbier A, Metta V, Titova N, Timmermann L, Ashkan K, Samuel M, Pekkonen E, Odin P, Antonini A, Martinez-Martin P, Parry M, van Wamelen DJ, Ray Chaudhuri K (2021) Personalised advanced therapies in Parkinson’s disease: the role of non-motor symptoms profile. J Personalized Med 11(8):773. https://doi.org/10.3390/jpm11080773

Article  Google Scholar 

Leta, V., Klingelhoefer, L., Longardner, K., Campagnolo, M., Levent, H. Ç., Aureli, F., Metta, V., Bhidayasiri, R., Chung-Faye, G., Falup-Pecurariu, C., Stocchi, F., Jenner, P., Warnecke, T., Ray Chaudhuri, K., International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group (2023).Gastrointestinal barriers to levodopa transport and absorption in Parkinson’s disease. European journal ofneurology, 30 (5) 1465–1480. Doi https://doi.org/10.1111/ene.15734

Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C (2017) Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain and Behavior 7(5):e00698. https://doi.org/10.1002/brb3.698

Article  PubMed  PubMed Central  Google Scholar 

Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, Chaudhuri KR (2017) The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ 20(11):1207–1215. https://doi.org/10.1080/13696998.2017.1379411

Article  PubMed  Google Scholar 

Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES (2017) Consensus on the definition of advanced Parkinson’s disease: A Neurologists-based delphi study (CEPA Study). Parkinson’s Disease 2017:4047392. https://doi.org/10.1155/2017/4047392

Article  PubMed  PubMed Central  Google Scholar 

Malek N, Grosset DG (2015) Medication adherence in patients with Parkinson’s disease. CNS Drugs 29(1):47–53. https://doi.org/10.1007/s40263-014-0220-0

Article  CAS  PubMed  Google Scholar 

Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, Jenner P (2003) Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179(1):90–102. https://doi.org/10.1006/exnr.2002.8055

Article  CAS  PubMed  Google Scholar 

Martinez-Martin, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., Odin, P., Henriksen, T., Martin, A., Calandrella, D., Rizos, A., Bryndum, N., Glad, A., Dafsari, H. S., Timmermann, L., Ebersbach, G., Kramberger, M. G., Samuel, M., Wenzel, K., Tomantschger, V., Storch, A., Chaudhuri, KR., (2015). EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Movement disorders. Official Journal of the Movement Disorder Society, 30 (4) 510–516. Doi https://doi.org/10.1002/mds.26067

Masood N, Jimenez-Shahed J (2023) Effective management of “OFF” episodes in Parkinson’s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr Dis Treat 19:247–266. https://doi.org/10.2147/NDT.S273121

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, Dodet P, Méneret A, Mariani LL, Delorme C, Cormier-Dequaire F, Bendetowicz D, Villain N, Tarrano C, Mantisi L, Letrillart H, Louapre C, McGovern E, Worbe Y, Grabli D, Roze E (2021) Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study. NPJ Parkinson’s Disease 7(1):50. https://doi.org/10.1038/s41531-021-00194-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L (2016) Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 23(3):501–509. https://doi.org/10.1111/ene.12846

Article  CAS  PubMed